S Ludwig1,2, D Kalbacher3,4, N Schofer3, A Schäfer5, B Koell3, M Seiffert3,4, J Schirmer5, U Schäfer6, D Westermann3,4, H Reichenspurner4,5, S Blankenberg3,4, E Lubos3, L Conradi4,5. 1. Department of Cardiology, University Heart and Vascular Center Hamburg, Martinistrasse 52, 20246, Hamburg, Germany. se.ludwig@uke.de. 2. Partner Site Hamburg/Kiel/Lübeck, German Centre for Cardiovascular Research (DZHK), Hamburg, Germany. se.ludwig@uke.de. 3. Department of Cardiology, University Heart and Vascular Center Hamburg, Martinistrasse 52, 20246, Hamburg, Germany. 4. Partner Site Hamburg/Kiel/Lübeck, German Centre for Cardiovascular Research (DZHK), Hamburg, Germany. 5. Department of Cardiovascular Surgery, University Heart and Vascular Center Hamburg, Hamburg, Germany. 6. Marienkrankenhaus Hamburg, Department of Cardiology, Angiology and Intensive Care, Hamburg, Germany.
Abstract
AIMS: Transcatheter mitral valve replacement (TMVR) with dedicated devices promises to fill the treatment gap between open-heart surgery and edge-to-edge repair for patients with severe mitral regurgitation (MR). We herein present a single-centre experience of a TMVR series with two transapical devices. METHODS AND RESULTS: A total of 11 patients were treated with the Tendyne™ (N = 7) or the Tiara™ TMVR systems (N = 4) from 2016 to 2020 either as compassionate-use procedures or as commercial implants. Clinical and echocardiographic data were collected at baseline, discharge and follow-up and are presented in accordance with the Mitral Valve Academic Research Consortium (MVARC) definitions. The study cohort [age 77 years (73, 84); 27.3% male] presented with primary (N = 4), secondary (N = 5) or mixed (N = 2) MR etiology. Patients were symptomatic (all NYHA III/IV) and at high surgical risk [logEuroSCORE II 8.1% (4.0, 17.4)]. Rates of impaired RV function (72.7%), severe pulmonary hypertension (27.3%), moderate or severe tricuspid regurgitation (63.6%) and prior aortic valve replacement (63.6%) were high. Severe mitral annulus calcification was present in two patients. Technical success was achieved in all patients. In 90.9% (N = 10) MR was completely eliminated (i.e. no or trace MR). Procedural and 30-day mortality were 0.0%. At follow-up NYHA class was I/II in the majority of patients. Overall mortality after 3 and 6 months was 10.0% and 22.2%. CONCLUSIONS: TMVR was performed successfully in these selected patients with complete elimination of MR in the majority of patients. Short-term mortality was low and most patients experienced persisting functional improvement.
AIMS: Transcatheter mitral valve replacement (TMVR) with dedicated devices promises to fill the treatment gap between open-heart surgery and edge-to-edge repair for patients with severe mitral regurgitation (MR). We herein present a single-centre experience of a TMVR series with two transapical devices. METHODS AND RESULTS: A total of 11 patients were treated with the Tendyne™ (N = 7) or the Tiara™ TMVR systems (N = 4) from 2016 to 2020 either as compassionate-use procedures or as commercial implants. Clinical and echocardiographic data were collected at baseline, discharge and follow-up and are presented in accordance with the Mitral Valve Academic Research Consortium (MVARC) definitions. The study cohort [age 77 years (73, 84); 27.3% male] presented with primary (N = 4), secondary (N = 5) or mixed (N = 2) MR etiology. Patients were symptomatic (all NYHA III/IV) and at high surgical risk [logEuroSCORE II 8.1% (4.0, 17.4)]. Rates of impaired RV function (72.7%), severe pulmonary hypertension (27.3%), moderate or severe tricuspid regurgitation (63.6%) and prior aortic valve replacement (63.6%) were high. Severe mitral annulus calcification was present in two patients. Technical success was achieved in all patients. In 90.9% (N = 10) MR was completely eliminated (i.e. no or trace MR). Procedural and 30-day mortality were 0.0%. At follow-up NYHA class was I/II in the majority of patients. Overall mortality after 3 and 6 months was 10.0% and 22.2%. CONCLUSIONS:TMVR was performed successfully in these selected patients with complete elimination of MR in the majority of patients. Short-term mortality was low and most patients experienced persisting functional improvement.
Authors: Mitsunobu Kitamura; Hidehiro Kaneko; Michael Schlüter; Dimitry Schewel; Tobias Schmidt; Hannes Alessandrini; Felix Kreidel; Michael Neuss; Christian Butter; Karl-Heinz Kuck; Christian Frerker Journal: Clin Res Cardiol Date: 2018-08-10 Impact factor: 5.460
Authors: Hiroki Niikura; Mario Gössl; Vibhu Kshettry; Sara Olson; Benjamin Sun; Judah Askew; Larissa Stanberry; Ross Garberich; Liang Tang; John Lesser; Richard Bae; Kevin M Harris; Steven M Bradley; Paul Sorajja Journal: JACC Cardiovasc Interv Date: 2019-01-28 Impact factor: 11.195
Authors: Helmut Baumgartner; Volkmar Falk; Jeroen J Bax; Michele De Bonis; Christian Hamm; Per Johan Holm; Bernard Iung; Patrizio Lancellotti; Emmanuel Lansac; Daniel Rodriguez Muñoz; Raphael Rosenhek; Johan Sjögren; Pilar Tornos Mas; Alec Vahanian; Thomas Walther; Olaf Wendler; Stephan Windecker; Jose Luis Zamorano Journal: Eur Heart J Date: 2017-09-21 Impact factor: 29.983
Authors: Anson Cheung; John Webb; Stefan Verheye; Robert Moss; Robert Boone; Jonathan Leipsic; Ron Ree; Shmuel Banai Journal: J Am Coll Cardiol Date: 2014-10-21 Impact factor: 24.094
Authors: Paul Sorajja; Mario Gössl; Vasilis Babaliaros; David Rizik; Lenard Conradi; Richard Bae; Robert F Burke; Ulrich Schäfer; John C Lisko; Robert D Riley; Robert Guyton; Nicolas Dumonteil; Pierre Berthoumieu; Didier Tchetche; Philipp Blanke; João L Cavalcante; Benjamin Sun Journal: J Am Coll Cardiol Date: 2019-09-17 Impact factor: 24.094
Authors: Christine S Zuern; Axel Bauer; Edith Lubos; Peter Boekstegers; Miriam Puls; Ralph Stephan V Bardeleben; Taoufik Ouarrak; Christian Butter; Holger Eggebrecht; Georg Nickenig; Ralph Zahn; Jochen Senges; Andreas E May Journal: Clin Res Cardiol Date: 2015-05-29 Impact factor: 5.460
Authors: Philipp Blanke; Danny Dvir; Anson Cheung; Jian Ye; Robert A Levine; Bruce Precious; Adam Berger; Dion Stub; Cameron Hague; Darra Murphy; Christopher Thompson; Brad Munt; Robert Moss; Robert Boone; David Wood; Gregor Pache; John Webb; Jonathon Leipsic Journal: J Cardiovasc Comput Tomogr Date: 2014-10-07
Authors: Alina Zubarevich; Marcin Szczechowicz; Konstantin Zhigalov; Philipp Marx; Alexander Lind; Rolf Alexander Jánosi; Tienush Rassaf; Sharaf-Eldin Shehada; Rizwan Malik; Markus Kamler; Matthias Thielmann; Bastian Schmack; Arjang Ruhparwar; Alexander Weymann; Daniel Wendt Journal: Ann Cardiothorac Surg Date: 2021-09
Authors: Matti Adam; Elmar Kuhn; Hendrik Wienemann; Victor Mauri; Laurin Ochs; Maria Isabel Körber; Kaveh Eghbalzadeh; Christos Iliadis; Marcel Halbach; Thorsten Wahlers; Stephan Baldus Journal: Clin Res Cardiol Date: 2022-09-15 Impact factor: 6.138
Authors: Johannes Petersen; Shiho Naito; Benjamin Kloth; Simon Pecha; Svante Zipfel; Yousuf Alassar; Christian Detter; Lenard Conradi; Hermann Reichenspurner; Evaldas Girdauskas Journal: Front Cardiovasc Med Date: 2022-09-30